XENEXenon Pharmaceuticals Inc

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...

Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...

Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options...

Xenon Pharmaceuticals (NASDAQ:XENE) provided an update on its clinical and pipeline progress at the Bloom Burton conference, with CEO Ian Mortimer highlighting recent Phase III results for lead program azetukalner, plans for regulatory filings, and continued expansion into psychiatry and pain. Lead...

Peregrine Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent...